Holen Sie sich die Stockscreener-App
19.41
3.52%
0.66
Vorhandelsmarkt:
20.46
1.05
+5.41%
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Aug PreEarnings: What is the next catalyst for Nurix Therapeutics Inc2025 Earnings Surprises & Technical Analysis for Trade Confirmation - baoquankhu1.vn
EPS Watch: Will Nurix Therapeutics Inc outperform the market in YEARJuly 2025 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
Insider Buy: Can Nurix Therapeutics Inc sustain its profitability2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Insider Buy: Will Nurix Therapeutics Inc outperform the market in YEARMarket Trend Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility - Yahoo Finance
(NRIX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Cuts Target Price to $28 - 富途牛牛
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock - Investing.com
RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk - marketscreener.com
Nurix Therapeutics (NRIX) to Release Earnings on Tuesday - MarketBeat
Market Rankings: What is the next catalyst for Nurix Therapeutics IncJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know - sharewise.com
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The AI Journal
Aug Fed Impact: Is Contango Ore Inc attractive for institutional investorsJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
BTIG reiterates Buy rating on Nurix stock with $30 price target - Investing.com UK
Sectors Review: Is Nurix Therapeutics Inc a stock for growth or value investorsJuly 2025 Movers & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Volume Summary: Why Nurix Therapeutics Inc. stock could outperform in 2025 - Bộ Nội Vụ
Nurix outlines 2026 strategy for BTK degrader bexobrutideg in pivotal trials - Investing.com Nigeria
Do Analyst Upgrades Clarify Nurix Therapeutics’ (NRIX) True Potential Or Complicate Its Valuation Story? - Sahm
NRIX: Bexabrutadeg shows best-in-class potential in CLL, driving pivotal trials and pipeline expansion - TradingView — Track All Markets
Nurix Therapeutics, Inc. Outlines 2026 Goals and Objectives - TradingView — Track All Markets
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - Investing News Network
Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha
Nurix outlines 2026 strategy for BTK degrader bexobrutideg in pivotal trials By Investing.com - Investing.com South Africa
Inside Nurix's push to test a new cancer and autoimmune drug in 2026 - Stock Titan
Published on: 2026-01-10 21:09:42 - ulpravda.ru
Why retail investors pile into Nurix Therapeutics Inc. stockEarnings Growth Report & Fast Entry and Exit Trade Plans - ulpravda.ru
Aug Patterns: Why Nurix Therapeutics Inc. stock appeals to analystsPortfolio Gains Summary & Daily Stock Momentum Reports - Улправда
How Nurix Therapeutics Inc. stock compares to market leadersPortfolio Profit Report & Low Risk Entry Point Guides - ulpravda.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 59% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
What 18 Analyst Ratings Have To Say About Nurix Therapeutics - Sahm
Morgan Stanley Upgrades Nurix Therapeutics (NRIX) - Nasdaq
Dow Theory LettersNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Detailed Stock Data - FinancialContent
Will Nurix Therapeutics Inc. stock beat EPS estimates2025 Major Catalysts & Precise Swing Trade Entry Alerts - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpStill a Buy? - MarketBeat
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
Should I hold or sell Nurix Therapeutics Inc. stock in 20252026 world cup usa national team round of 32 goalkeepers high defensive line winner prediction statistical analysis - ulpravda.ru
User | ricentral.comNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Stock Quote - FinancialContent
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
NRIX Stock Price, Forecast & Analysis | NURIX THERAPEUTICS INC (NASDAQ:NRIX) - Chartmill
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):